Close Menu

John Cucci, Steve Kamalic, Zaleena Neice

Jan 18, 2017

Acupath Laboratories has appointed John Cucci as chief sales officer, Steve Kamalic as chief operating officer, and Zaleena Neice as CFO. Cucci previously served as director of business development for Acupath. Prior to joining the company, he served in senior sales leadership roles at several labs, including P4 Diagnostix, formerly Theranostix; VitalAxis, PLUS Diagnostics, and Dianon Pathology, subsidiary of LabCorp. Kamalic previously worked as director of sales for Acupath. Neice previously served as controller for Acupath.

More Like This

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18. 

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America. 

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

May 12, 2020

Alveo Technologies: Bharat Tewarie

Alveo Technologies has appointed Bharat Tewarie to its board of directors. Tewarie recently founded Boston BioPharma Consultants and was formerly executive vice president and chief marketing officer at biopharma firm UCB. He currently is on the board of Ahara Biosciences and Duluth Medical Technologies. Alameda, California-based Alveo is developing an at-home diagnostic platform called be.well that leverages nucleic acid amplification for the molecular detection of infectious diseases.

May 11, 2020

Roche: Fritz Gerber

Roche announced that former Group CEO and Chairman of the Board Fritz Gerber died at 92. Gerber served as group CEO from 1978 to 1998 and decentralized the company's structures. Under his leadership, Roche acquired a majority stake in Genentech, took over Boehringer Mannheim, and acquired PCR technology. After retiring as chairman in 2001, he remained an honorary chairman throughout the rest of his life. 

Gerber was also on the board of IBM and created the Fritz Gerber Foundation for Gifted Young People.

May 06, 2020

Centogene: Angelos Baxevanis

Angelos Baxevanis has joined Centogene as senior vice president of communication and marketing. He joins the company from AAB Consulting, where he worked with Sobi Pharmaceuticals on enhancing commercial capabilities for rare disease. Prior to that, he led marketing communication and excellence at Smith & Nephew, and before that, he held several positions at Astra Zeneca. Baxevanis has an MBA from the Alba Graduate Business School and a master's degree in chemical engineering from the University of Patras in Greece.

May 06, 2020

OraSure Technologies: Lisa Nibauer

OraSure Technologies has appointed Lisa Nibauer as executive vice president and business unit leader for infectious disease. She will replace Tony Zezzo, who has announced that he will retire from the company. Zezzo's official retirement date will be mutually determined, and he will maintain his current role in OraSure's COVID-19 activities while he coordinates the transition with Nibauer, who will join the company on May 11. Nibauer most recently served as vice president and general manager of global medication delivery solutions at Becton Dickinson.

May 06, 2020

First Light Diagnostics: Joanne Spadoro

First Light Diagnostics announced that Joanne Spadoro is the company's COO. Last September she joined the company as VP of R&D and regulatory affairs. Previously, Spadoro was senior VP of product development and operations at Roche Molecular Systems, leading the teams that launched PCR-based products globally for infectious disease diagnostics, viral load monitoring, and blood screening applications. 

She also served as CSO and worldwide VP of operations at Immucor, developing the company's molecular immunohematology test for the detection of extended blood antigens. Spadoro was also previously the COO at T2 Biosystems. 

May 05, 2020

Grail: Mostafa Ronaghi

Mostafa Ronaghi has joined Grail's board of directors. Ronaghi is currently Illumina's senior vice president of entrepreneurial development, and previously served as the company's senior VP and chief technology officer, a role in which he led internal research and technology and cofounded Grail. He also cofounded the Illumina Accelerator.

In 2007, Ronaghi cofounded Avantome, a privately held sequencing company that was acquired by Illumina in 2008. Before this, he cofounded NextBio, a search engine for life science data that was acquired by Illumina in 2013. In 2001, Ronaghi cofounded ParAllele Bioscience, which was eventually acquired by Affymetrix, and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997 he cofounded Pyrosequencing AB, which was renamed Biotage in 2003. Ronaghi earned his PhD from the Royal Institute of Technology in Sweden and was a principal investigator at Stanford University from 2002 until 2008, focused on the development of novel tools for molecular diagnostic applications. He also serves on the board of directors of BaseHealth and Clear Labs. 

May 04, 2020

Oncimmune: Richard Sharp

Oncimmune Holdings announced Richard Sharp has stepped down as a non-executive director of the firm, effective May 4, in order to focus on his new role as senior strategic adviser to the UK government in connection with the coronavirus pandemic. Sharp remains a shareholder in Oncimmune.

Apr 29, 2020

Transplant Genomics: Peter Meintjes

Eurofins-Transplant Genomics has appointed Peter Meintjes as chief commercial officer to lead the commercialization of the company's TruGraf blood test for kidney transplant surveillance. Meintjes joins TGI after six years at Omixon, where most recently served as CEO after having also held the roles of chief commercial officer and director of US operations. Meintjes also previously worked as VP of business development for Biomatters.

Apr 29, 2020

Grail: Satnam Alag

Grail has appointed Satnam Alag as senior VP of software engineering. Prior to Grail, Alag most recently served as VP of software engineering, product development at Illumina. Before Illumina, Alag was chief technology officer at NextBio, which was acquired by Illumina in 2013. Alag has also held other senior software architecture positions, including chief software architect at Deem.  

Apr 24, 2020

HTG Molecular Diagnostics: Maureen Cronin

Maureen Cronin has resigned as CSO and senior VP at HTG Molecular Diagnostics, effective April 30. She will resume her consulting practice to pursue other interests, the company said. Cronin joined HTG Molecular in November 2018 after serving as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior VP of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Apr 21, 2020

Sense Biodetection: John Bishop

Sense Biodetection appointed John Bishop as a non-executive director.

Bishop, Cepheid's CEO from 2002 until its acquisition by Danaher in 2016, will play a pivotal strategic role at Sense as the company rapidly scales up production and distribution of its first products, including its COVID-19 test, Veros SARS-CoV-2.

At Cepheid, Bishop was instrumental in accelerating the firm's growth as a molecular diagnostics company. He oversaw the successful launch and commercialization of its GeneXpert and GeneXpert Xpress systems.

Apr 21, 2020

Truvian Sciences: Jean-Pierre Millon

Truvian Sciences appointed Jean-Pierre Millon to its board of directors. He is currently also a board member at CVS Health and was president and CEO of PCS. He previously held leadership positions at Eli Lilly and is a cofounder of consuting and investing firm BLS.